Karin Hardt

8.2k total citations
44 papers, 1.9k citations indexed

About

Karin Hardt is a scholar working on Epidemiology, Infectious Diseases and Microbiology. According to data from OpenAlex, Karin Hardt has authored 44 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Epidemiology, 11 papers in Infectious Diseases and 9 papers in Microbiology. Recurrent topics in Karin Hardt's work include Hepatitis B Virus Studies (12 papers), Cervical Cancer and HPV Research (9 papers) and Bacterial Infections and Vaccines (8 papers). Karin Hardt is often cited by papers focused on Hepatitis B Virus Studies (12 papers), Cervical Cancer and HPV Research (9 papers) and Bacterial Infections and Vaccines (8 papers). Karin Hardt collaborates with scholars based in Belgium, United States and United Kingdom. Karin Hardt's co-authors include Gary Dubin, Dominique Descamps, Bart Spiessens, Thomas Verstraeten, Patricia Izurieta, Thomas Breuer, Pierre Van Damme, Marie‐Pierre David, Koen Van Herck and Toufik Zahaf and has published in prestigious journals such as Proceedings of the National Academy of Sciences, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

Karin Hardt

44 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karin Hardt Belgium 23 1.1k 545 382 368 269 44 1.9k
J E Banatvala United Kingdom 30 1.6k 1.4× 826 1.5× 114 0.3× 757 2.1× 282 1.0× 88 2.5k
Talat Mokhtari‐Azad Iran 25 1.1k 0.9× 604 1.1× 144 0.4× 143 0.4× 293 1.1× 165 1.9k
Eftyhia Vardas South Africa 23 1.5k 1.3× 493 0.9× 630 1.6× 193 0.5× 440 1.6× 52 2.4k
Alexandra Valsamakis United States 31 1.9k 1.7× 883 1.6× 96 0.3× 351 1.0× 380 1.4× 71 2.8k
Jessica Leung United States 23 1.5k 1.3× 520 1.0× 359 0.9× 136 0.4× 127 0.5× 95 2.1k
Radha Railkar United States 18 2.2k 2.0× 274 0.5× 897 2.3× 128 0.3× 412 1.5× 35 2.7k
Luc Hessel France 18 642 0.6× 336 0.6× 87 0.2× 125 0.3× 171 0.6× 36 1.2k
Igor Smolenov United States 20 588 0.5× 1.0k 1.8× 56 0.1× 276 0.8× 248 0.9× 59 1.7k
Jesús Ruíz-Contreras Spain 24 1.1k 1.0× 502 0.9× 146 0.4× 71 0.2× 367 1.4× 146 1.9k
Josep Costa Spain 29 2.4k 2.2× 575 1.1× 233 0.6× 2.1k 5.8× 183 0.7× 104 3.3k

Countries citing papers authored by Karin Hardt

Since Specialization
Citations

This map shows the geographic impact of Karin Hardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Hardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Hardt more than expected).

Fields of papers citing papers by Karin Hardt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Hardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Hardt. The network helps show where Karin Hardt may publish in the future.

Co-authorship network of co-authors of Karin Hardt

This figure shows the co-authorship network connecting the top 25 collaborators of Karin Hardt. A scholar is included among the top collaborators of Karin Hardt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karin Hardt. Karin Hardt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jacqmin, Philippe, Yuki Iwaki, Mathieu Le Gars, et al.. (2023). Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID‐19 vaccine Ad26.COV2.S in humans. CPT Pharmacometrics & Systems Pharmacology. 12(10). 1485–1498. 4 indexed citations
2.
Skowron, Margaretha A., Patrick Petzsch, Karin Hardt, et al.. (2019). Distinctive mutational spectrum and karyotype disruption in long-term cisplatin-treated urothelial carcinoma cell lines. Scientific Reports. 9(1). 14476–14476. 10 indexed citations
3.
Hardt, Karin, Paolo Bonanni, Susan Codi King, et al.. (2016). Vaccine strategies: Optimising outcomes. Vaccine. 34(52). 6691–6699. 87 indexed citations
4.
Li, Rongcheng, Yanping Li, Youping Liu, et al.. (2016). Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China. Vaccine. 34(12). 1436–1443. 9 indexed citations
5.
6.
Hens, Niel, et al.. (2014). Model based estimates of long-term persistence of inactivated hepatitis A vaccine-induced antibodies in adults. Vaccine. 32(13). 1507–1513. 48 indexed citations
7.
8.
Herck, Koen Van, Priya Diana Crasta, Marc Messier, Karin Hardt, & Pierre Van Damme. (2012). Seventeen-year antibody persistence in adults primed with two doses of an inactivated hepatitis A vaccine. Human Vaccines & Immunotherapeutics. 8(3). 323–327. 23 indexed citations
9.
Damme, Pierre Van, Peter McIntyre, E. Grimprel, et al.. (2011). Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix®) in adults 55 years of age and over: A sub-analysis of four trials. Vaccine. 29(35). 5932–5939. 20 indexed citations
10.
Leube, Barbara, Karin Hardt, Bettina Westhoff, et al.. (2008). Ulna/Height Ratio as Clinical Parameter Separating EXT1 from EXT2 Families?. Genetic Testing. 12(1). 129–133. 5 indexed citations
11.
Pedersen, C, Tiina Petäjä, Gitte Strauss, et al.. (2007). Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant.. Journal of Child and Adolescent Mental Health. 40. 564–571. 5 indexed citations
12.
Jäger, Markus, Bettina Westhoff, Barbara Leube, et al.. (2007). Clinical outcome and genotype in patients with hereditary multiple exostoses. Journal of Orthopaedic Research®. 25(12). 1541–1551. 35 indexed citations
13.
Pedersen, Court, Tiina Petäjä, Gitte Strauss, et al.. (2007). Immunization of Early Adolescent Females with Human Papillomavirus Type 16 and 18 L1 Virus-Like Particle Vaccine Containing AS04 Adjuvant. Journal of Adolescent Health. 40(6). 564–571. 192 indexed citations
14.
Phua, Kong Boo, Seng Hock Quak, S C Emmanuel, et al.. (2006). A short report on highlights of worldwide development of RIX4414: A Singaporean experience. Vaccine. 24(18). 3782–3783. 9 indexed citations
15.
Linhares, A. C., Guillermo M. Ruiz‐Palacios, M. Lourdes Guerrero, et al.. (2005). A short report on highlights of world-wide development of RIX4414: A Latin American experience. Vaccine. 24(18). 3784–3785. 23 indexed citations
16.
Salinas, Beatriz, Irene Pérez Schael, Alexandre C. Linhares, et al.. (2005). Evaluation of Safety, Immunogenicity and Efficacy of an Attenuated Rotavirus Vaccine, RIX4414. The Pediatric Infectious Disease Journal. 24(9). 807–816. 167 indexed citations
17.
Vos, Béatrice De, Timo Vesikari, Alexandre C. Linhares, et al.. (2004). A Rotavirus Vaccine for Prophylaxis of Infants Against Rotavirus Gastroenteritis. The Pediatric Infectious Disease Journal. 23(10). S179–S182. 124 indexed citations
18.
Pfeiffer, R. A., Anita Rauch, Udo Trautmann, et al.. (1999). Defective sexual development in an infant with 46, XY, der(9)t(8;9)(q23.1;p23)mat. European Journal of Pediatrics. 158(3). 213–216. 9 indexed citations
19.
20.
Deetjen, P., et al.. (1968). Die Glucoseresorption in der Rattenniere: Mikropunktionsanalysen der tubulren Glucosekonzentration bei freiem Flu. Pflügers Archiv - European Journal of Physiology. 302(3). 219–232. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J E Banatvala Breakdown of academic impact, for papers by Talat Mokhtari‐Azad Breakdown of academic impact, for papers by Eftyhia Vardas Breakdown of academic impact, for papers by Alexandra Valsamakis Breakdown of academic impact, for papers by Jessica Leung Breakdown of academic impact, for papers by Radha Railkar Breakdown of academic impact, for papers by Luc Hessel Breakdown of academic impact, for papers by Igor Smolenov Breakdown of academic impact, for papers by Jesús Ruíz-Contreras Breakdown of academic impact, for papers by Josep Costa
Rankless by CCL
2026